5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Non-Hodgkin Lymphoma Therapeutics Market is Segmented by Type of Therapy (Chemotherapy, Radiation Therapy, Targeted Therapy, and Other Types of Therapies), Cell Type, and Geography.
Fastest Growing Market:
Certain factors that are driving the market growth include a rise in the prevalence of NHL, demand for innovative drugs and novel technologies, and an increase in the number of FDA approvals for NHL therapy drugs.
Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or just lymphoma) is a type of cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system. NHL usually starts in lymph nodes or other lymph tissues, but sometimes it can affect the skin.
|By Type of Therapy|
|Other Types of Therapies|
|By Cell Type|
Report scope can be customized per your requirements. Click here.
Radiotherapy is the use of high-energy beams or particles to kill cancer cells, and it can be delivered from a source outside the body, i.e., external beam radiation or internally, such as brachytherapy. Usually, radiation treatments are given five days per week for several weeks. Radiation therapy is most effective when this kind of lymphoma is only found in one part of the body. According to the American Cancer Society, non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States that accounts for about 4% of all cancers. For non-Hodgkin disease, radiation therapy is used in the early stages. In the case of advanced lymphomas, radiation therapy is used along with chemotherapy for better treatment of NHL. If the lymphoma is widespread, palliative radiotherapy is very helpful. Radiotherapy is often very good at destroying non-Hodgkin disease cells. It mainly helps in relieving the symptoms caused by the lymphomas.
To understand key trends, Download Sample Report
By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and South America. North America dominates the non-Hodgkin lymphoma therapeutics market, due to increasing technological advancements and the rising incidences of NHL in the country. However, Asia-Pacific is expected to propel the non-Hodgkin lymphoma therapeutics market, owing to factors, such as increasing accessibility to healthcare facilities in the region and increasing prevalence of NHL. According to the research article published in 2018, it was estimated that the incidence rate of non-Hodgkin lymphoma was 7.11 per 100,000 per year in China. As the incidence and prevalence of non-Hodgkin lymphoma are increasing Y-o-Y, many manufacturing companies are investing to develop novel drug therapies to meet the growing demand for therapeutics. Hence, with the growing awareness of the disease, increasing government initiatives, and an increase in the burden of disease, the market is expected to grow over the forecast period.
To understand geography trends, Download Sample Report.
The non-Hodgkin lymphoma therapeutics market is highly competitive and consists of a few major players. Companies, like AstraZeneca, Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Eli Lilly and Co., F. Hoffmann La-Roche Ltd, GlaxoSmithKline PLC, hold substantial market shares in the non-Hodgkin lymphoma therapeutics market.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Non-Hodgkin Lymphoma (NHL)
4.2.2 Demand for Innovative Drugs and Novel Technologies
4.3 Market Restraints
4.3.1 High Cost of the Drugs Used in NHL Therapy
4.3.2 Side Effects Associated with NHL Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Type of Therapy
5.1.2 Radiation Therapy
5.1.3 Targeted Therapy
5.1.4 Other Types of Therapies
5.2 By Cell Type
5.2.1 B-cell Lymphomas
5.2.2 T-cell Lymphoma
5.3 By Geography
5.3.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle-East and Africa
5.3.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AstraZeneca PLC
6.1.2 Baxter International Inc.
6.1.3 Bayer AG
6.1.4 Bristol Myers Squibb Company
6.1.5 Eli Lilly and Company
6.1.6 F. Hoffmann La-Roche Ltd
6.1.7 GlaxoSmithKline PLC
6.1.8 Seattle Genetics
6.1.9 Teva Pharmaceuticals
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments